Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Endra Life Sciences Inc (NDRA)

Endra Life Sciences Inc (NDRA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.98 +0.53 (+15.36%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 3.90 -0.08 (-2.01%) 19:57 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.49
Day High
4.33
Open 3.49
Previous Close 3.45 3.45
Volume 644,000 644,000
Avg Vol 357,525 357,525
Stochastic %K 24.11% 24.11%
Weighted Alpha -87.02 -87.02
5-Day Change +0.31 (+8.45%) +0.31 (+8.45%)
52-Week Range 2.97 - 664.83 2.97 - 664.83
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,940
  • Shares Outstanding, K 562
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,510 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -3.91
  • Number of Estimates 1
  • High Estimate -3.91
  • Low Estimate -3.91
  • Prior Year -454.55
  • Growth Rate Est. (year over year) +99.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.97 +34.01%
on 04/22/25
Period Open: 4.30
6.15 -35.28%
on 04/07/25
-0.32 (-7.44%)
since 03/25/25
3-Month
2.97 +34.01%
on 04/22/25
Period Open: 5.63
6.15 -35.28%
on 04/07/25
-1.65 (-29.31%)
since 01/24/25
52-Week
2.97 +34.01%
on 04/22/25
Period Open: 424.38
664.83 -99.40%
on 05/02/24
-420.39 (-99.06%)
since 04/25/24

Most Recent Stories

More News
ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months ended...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Securities

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today the closing of its previously announced underwritten...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today that it has priced an underwritten public offering...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three months and year ended December 31, 2022, and provided...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months and year...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Announces 1-for-20 Reverse Stock Split

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today that it will be effecting a reverse stock split of its outstanding...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three and nine months ended September 30, 2022, and provided...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Report Third Quarter 2022 Financial Results on November 14, 2022

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the third quarter of 2022...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents

ENDRA Life Sciences Inc. (NASDAQ: NDRA) , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the United States Patent and Trademark Office has issued two new ENDRA patents, U.S....

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that management will present a company overview at the H.C. Wainwright...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Plans to Submit De Novo Request to U.S. FDA for its TAEUS® System in Coming Weeks

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces an update to its plan to submit a De Novo request for the TAEUS...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Participate in Upcoming Investor and Industry Conferences

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that management will present a company overview at the H.C. Wainwright...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the European Patent Office has issued European Patent...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three and six months ended June 30, 2022, and provided a...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Report Second Quarter 2022 Financial Results on August 15, 2022

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2022 on Monday,...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the United States Patent & Trademark Office has issued three...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Awarded Two Additional Chinese Patents for its TAEUS® System

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the Chinese National Intellectual Property Administration has issued two new patents...

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent

ENDRA Life Sciences Inc. (NASDAQ: NDRA) , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S....

NDRA : 3.98 (+15.36%)
ENDRA Life Sciences to Participate in the JMP Securities Life Sciences Conference

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the JMP Securities Life Sciences Conference being held...

NDRA : 3.98 (+15.36%)

Business Summary

ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States.

See More

Key Turning Points

3rd Resistance Point 5.22
2nd Resistance Point 4.77
1st Resistance Point 4.38
Last Price 3.98
1st Support Level 3.54
2nd Support Level 3.09
3rd Support Level 2.69

See More

52-Week High 664.83
Fibonacci 61.8% 412.00
Fibonacci 50% 333.90
Fibonacci 38.2% 255.80
Last Price 3.98
52-Week Low 2.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.